Common Contracts
5 similar Sales Agreement contracts by Innate Pharma SA, DBV Technologies S.A., Kala Pharmaceuticals, Inc., Solid Biosciences Inc.
SALES AGREEMENTSales Agreement • February 6th, 2024 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
SALES AGREEMENTSales Agreement • April 26th, 2023 • Innate Pharma SA • Biological products, (no disgnostic substances) • New York
SALES AGREEMENTSales Agreement • May 2nd, 2022 • DBV Technologies S.A. • Biological products, (no disgnostic substances) • New York
SALES AGREEMENTSales Agreement • November 3rd, 2021 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of the date first written above by Solid Biosciences Inc., a Delaware corporation (the “Company”), and Jefferies LLC (“Agent”), that are parties to that certain Sales Agreement, dated March 13, 2019 (the “Original Agreement”) relating to the offering of up to $50,000,000 of the Company’s Common Shares (as defined below).
KALA PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • August 9th, 2018 • Kala Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
